Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) shares stepped back 3.4% to $12.35 after the company reported the presentations of updated clinical results on BPX-501 in orphan inherited blood disorders and hematologic cancers. Share volume was 386,000, compared to an all-day average of 322,000
